Drugs / NBL-028
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06223256 | Mar 2024 → Jan 2027 expected | cancer or benign tumor | NovaRock Biotherapeutics, Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-10-25 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - NBL-028 FOR THE TREATMENT OF ADVANCED TUMORS OBTAINS CLINICAL TRIAL APPROVAL IN CHINA irasia.com ↗
NBL-028 FOR THE TREATMENT OF ADVANCED TUMORS OBTAINS CLINICAL TRIAL APPROVAL IN CHINA |
| 2023-08-17 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - NBL-028 FOR THE TREATMENT OF CLDN6 EXPRESSING ADVANCED TUMORS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. irasia.com ↗ |
| 2023-08-16 | NovaRock Biotherapeutics, Ltd | Regulatory NovaRock Biotherapeutics Announces FDA Approval of IND Application for NBL-028 novarockbio.com ↗
NovaRock Biotherapeutics Ltd, announced today that the U.S. Food and Drug Administration (FDA) issued a “study may proceed” letter for its investigational new drug (IND) application for NBL-028, a CLDN6-CD137 BsAb T Cell Engager. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-10-25 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - NBL-028 FOR THE TREATMENT OF ADVANCED TUMORS OBTAINS CLINICAL TRIAL APPROVAL IN CHINA irasia.com ↗ |
| 2023-08-17 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - NBL-028 FOR THE TREATMENT OF CLDN6 EXPRESSING ADVANCED TUMORS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. irasia.com ↗ |
| 2023-08-16 | NovaRock Biotherapeutics, Ltd | NovaRock Biotherapeutics Announces FDA Approval of IND Application for NBL-028 novarockbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NBL-028 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06223256 ↗ |
| Route | Intravenous | “Intravenous infusion (IV), once every two weeks (one treatment cycle is 4 weeks).” NCT06223256 ↗ |